Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients

Inclusion Criteria: * Patients submitted to a complete cytoreductive surgery and subsequent HIPEC for PMP * Histological diagnosis of pseudomyxoma peritonei (PMP) * Assessment of KRAS mutation positivity on surgical sample * Age \>= 18 years and \<76 years * Performance Status (ECOG \<2) * Adequate organ function including the following: * Adequate bone marrow reserve: WBC count \>3.0x109/L, absolute neutrophyl count \>1.5x109/L, platelet count \>100x109/L, and hemoglobin \>10 g/dL * Hepatic: bilirubin \< 1.5 times the ULN, alkaline phosphatase, aspartate transaminase, and alanine transaminase \< 2.5 xULN * Renal: Creatinine clearance \>50 mL/min or serum creatinine 1.5 x UNL * Patients compliance and geographic proximity that allows for adequate follow-up * Patients must sign an informed consent document (ICD) * Male and female patients with reproductive potential must use an approved contraceptive method. Exclusion Criteria: * Previous systemic chemotherapy and/or biological therapy * Administration of other experimental drugs during the study * Pregnancy and breast-feeding * Serious or uncontrolled medical pathologies or active infections that would jeopardize the possibility of receiving the investigated treatment * Disorders that could influence the absorption of capecitabine (e.g. malabsorption), intestinal occlusion, Crohn's disease or ulcerative colitis * Psychiatric disorders, neurologic disease or other conditions that would make it impossible to comply with the …